Sanofi (SNY) Operating Margin (2009 - 2026)
Sanofi's (SNY) quarterly Operating Margin came in at 20.18% in Q1 2026, down 291.0% year-on-year from 10.57% in Q1 2025, and down 63.88% quarter-over-quarter from 55.87% in Q4 2025.
Sanofi (SNY) Operating Margin (2009 - 2026) Analysis & Trends
Sanofi has disclosed Operating Margin across 18 years of filings, most recently posting 20.18% for Q1 2026.
- Operating Margin for Q1 2026 came in at 20.18%, down 291.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.0% (down 697.0% YoY), and the FY2025 annual result was 14.54%, down 311.0% from the prior year.
- Operating Margin came in at 20.18% for Q1 2026 at Sanofi, down from 55.87% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 55.87% in Q4 2025 to a low of 8.91% in Q4 2024.
- The 5-year median for Operating Margin is 21.82% (2022), against an average of 22.92%.
- Across the five-year window, Operating Margin plunged 2210 bps in 2023 and surged 4696 bps in 2025, its largest moves.
- Sanofi's Operating Margin stood at 38.26% in 2022, then slumped by 58 bps to 16.16% in 2023, then tumbled by 45 bps to 8.91% in 2024, then soared by 527 bps to 55.87% in 2025, then tumbled by 64 bps to 20.18% in 2026.
- The last three Operating Margin figures came in at 20.18% (Q1 2026), 55.87% (Q4 2025), and 22.84% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.58% |
| 10 | Sanofi | 63.47 Mn | -6.87 Bn | 9.49 Bn | 20.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.18% |
| Dec 31, 2025 | 55.87% |
| Sep 30, 2025 | 22.84% |
| Jun 30, 2025 | 14.75% |
| Mar 31, 2025 | 23.09% |
| Dec 31, 2024 | 8.91% |
| Sep 30, 2024 | 29.11% |
| Jun 30, 2024 | 16.25% |
| Mar 31, 2024 | 13.84% |
| Dec 31, 2023 | 16.16% |
| Sep 30, 2023 | 26.84% |
| Jun 30, 2023 | 18.66% |
| Mar 31, 2023 | 24.10% |
| Dec 31, 2022 | 38.26% |
| Sep 30, 2022 | 21.82% |
| Jun 30, 2022 | 14.16% |
| Mar 31, 2022 | 24.78% |
| Dec 31, 2021 | 14.75% |
| Sep 30, 2021 | 29.06% |
| Jun 30, 2021 | 17.60% |